This trial is active, not recruiting.

Condition meningitis
Treatment none administered in this study
Phase phase 4
Sponsor Sanofi
Start date July 2005
End date May 2013
Trial size 20000 participants
Trial identifier NCT00254995, MTA30


To further characterize the vaccine safety profile and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
none administered in this study
N/A in this study

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Receipt of Menactra vaccine during the study period. Exclusion Criteria: - None

Additional Information

Official title Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™)
Trial information was received from ClinicalTrials.gov and was last updated in February 2013.
Information provided to ClinicalTrials.gov by Sanofi.